BioCentury
ARTICLE | Company News

ChemoCentryx, Galenica deal

February 17, 2017 7:49 PM UTC

ChemoCentryx and Galenica’s Vifor Pharma company added rights in Asia and the Middle East to a 2016 licensing deal to commercialize avacopan (CCX168). Vifor now has rights to the compound worldwide outside of the U.S. and China, where Chemocentryx retains rights. ChemoCentryx will receive an additional $20 million upfront payment from Vifor under the expanded deal and is eligible for tiered double-digit royalties (see BioCentury, May 16, 2016)...